Organon & Co. (OGN)
NYSE: OGN · Real-Time Price · USD
8.54
-0.06 (-0.70%)
At close: Jan 30, 2026, 4:00 PM EST
8.48
-0.06 (-0.70%)
After-hours: Jan 30, 2026, 7:55 PM EST
Organon & Co. Revenue
Organon & Co. had revenue of $1.60B in the quarter ending September 30, 2025, with 1.26% growth. This brings the company's revenue in the last twelve months to $6.30B, down -1.69% year-over-year. In the year 2024, Organon & Co. had annual revenue of $6.40B with 2.24% growth.
Revenue (ttm)
$6.30B
Revenue Growth
-1.69%
P/S Ratio
0.35
Revenue / Employee
$630,100
Employees
10,000
Market Cap
2.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 6.40B | 140.00M | 2.24% |
| Dec 31, 2023 | 6.26B | 89.00M | 1.44% |
| Dec 31, 2022 | 6.17B | -130.00M | -2.06% |
| Dec 31, 2021 | 6.30B | -228.00M | -3.49% |
| Dec 31, 2020 | 6.53B | -1.25B | -16.01% |
| Dec 31, 2019 | 7.78B | -2.00B | -20.46% |
| Dec 31, 2018 | 9.78B | -723.00M | -6.89% |
| Dec 31, 2017 | 10.50B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Pfizer | 62.79B |
| Sanofi | 54.85B |
| Bristol-Myers Squibb Company | 48.03B |
| GSK plc | 43.24B |
| Biogen | 10.07B |
| Grifols | 8.82B |
| Amarin Corporation | 226.73M |
| Scilex Holding Company | 40.36M |
OGN News
- 3 days ago - Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026 - Business Wire
- 4 days ago - Organon Completes Divestiture of JADA® System to Laborie - Business Wire
- 12 days ago - Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report - Benzinga
- 15 days ago - Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque - Business Wire
- 24 days ago - Organon Enters into a Commercialization Agreement for Daiichi Sankyo's Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway - Business Wire
- 2 months ago - Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 2 months ago - Organon To Present at the Piper Sandler 37th Annual Healthcare Conference - Business Wire
- 2 months ago - Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US - Business Wire